Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 790

Results For "ED"

11235 News Found

Honeywell refurbishes PHCs in rural India across three states
Healthcare | June 01, 2023

Honeywell refurbishes PHCs in rural India across three states

The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana


Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData
News | May 31, 2023

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab


PharmaLytica returns to Hyderabad
News | May 31, 2023

PharmaLytica returns to Hyderabad

With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South


Capnopharm receives CE certification for its new CapnoPen technology
News | May 31, 2023

Capnopharm receives CE certification for its new CapnoPen technology

Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745


Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
News | May 30, 2023

Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores


Hikal posts FY23 PAT at Rs. 36 Cr
News | May 30, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22


NATCO records FY23 PAT at Rs. 715.3 Cr
News | May 30, 2023

NATCO records FY23 PAT at Rs. 715.3 Cr

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.


Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
News | May 29, 2023

Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239


Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
News | May 29, 2023

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore


Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies
News | May 29, 2023

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.